// App-Quantinova.ai

: ASPIRE Final Results Confirm Established Safety and Sustained Efficacy for Up to 4 Years of Treatment With rFVIIIFc in Previously Treated Subjects With Severe Hemophilia A

Researchers

Presenter

  • Beatrice Nolan

Principal Investigators

  • Johnny Mahlangu

  • Guy Young

  • Barbara A Konkle

  • K. John Pasi

  • Johannes Oldenburg

  • Keiji Nogami

  • Nikola Tripkovic

  • Huixing Yuan

  • Dan Rudin

Medical Centers

  • Our Lady's Children's Hospital, Dublin, Ireland

  • University of Witwatersrand, Johannesburg, South Africa

  • Children's Hosp Los Angeles, Los Angeles, CA

  • Bloodworks Northwest, Seattle, WA

  • Barts and the London Comprehensive Care Center, London, United Kingdom

  • Institute of Experimental Hematology and Transfusion Medicine, University Hospital Bonn, Bonn, Germany

  • Department of Surgery, Kansai Medical University, Hirakata, Japan

  • Sobi, Stockholm, Sweden

  • Bioverativ, a Sanofi Company, Waltham, MA, United States

  • Bioverativ, a Sanofi Company, Waltham, MA, United States

Locations

  • Ireland

  • South Africa

  • United States

  • United Kingdom

  • Germany

  • Japan

  • Sweden

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

  • Infectious Diseases (ID)

Disease

  • Hemophilia

  • Tuberculosis

Biomarkers

  • N/A

Drug/Treatment

  • FVIIIFc

Outcome

  • N/A

Study Design

  • Open Label

  • Multicenteric

Phase

  • III

Study Id's

  • NCT01181128

  • NCT01458106

  • NCT01454739

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved